RxDoctor Payments Data

Caressa Patel, PA

Physician Assistant · Bolivar, MONPI 1992123889

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Lilly USA, LLC accounts for 82.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $6,158 and has fallen 96.7% since, to $205 in 2025. Among physician assistant clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,058in general payments, 2019–2025

Across 128 payments — averaging $55.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$6K
  • AbbVie$670
  • Teva Pharmaceuticals USA, Inc.$181
  • Biohaven Pharmaceutical Holding Company Ltd.$153
  • Pfizer$129
  • Lundbeck LLC$44
  • plus $37 from 1 others

What the payments were for

  • Consulting fees$3,50050%
  • Travel & lodging$1,60423%
  • Food & beverage$1,86426%
  • Education$901%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,058 in reported general payments places this provider in the 95th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$23,986
Medicare patients
155
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant212$245,992
AustedoDeutetrabenazine15$233,073
Nurtec OdtRimegepant Sulfate130$141,850
Emgality PenGalcanezumab-Gnlm146$123,106
UbrelvyUbrogepant67$92,085
Aimovig AutoinjectorErenumab-Aooe61$51,393
Teriflunomide14$31,354
Ajovy AutoinjectorFremanezumab-Vfrm21$25,460
LamictalLamotrigine22$16,994
Rivastigmine48$6,418
Memantine Hcl286$4,051
Gabapentin201$3,436
Levetiracetam93$2,809
Primidone133$2,589
Fluoxetine Hcl14$2,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$670$338,077279 claims
Teva Pharmaceuticals USA, Inc.Austedo$181$233,07315 claims
PfizerNurtec Odt$129$141,850130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Bolivar

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →